STOCKHOLM, Sweden, Oct. 27, 2005 (PRIMEZONE) -- Vitrolife:
- Turnover increased to SEK 90.0 (79.3) million, an increase of 14 percent. During the third quarter sales increased by 21 percent to SEK 29.2 (24.1) million.
- Gross income increased by 9 percent to SEK 62.0 (56.9) million and the gross margin amounted to 69 (72) percent. Gross income for the third quarter increased by 14 percent to SEK 20.2 (17.6) million and the gross margin was 69 (73) percent.
- Operating income amounted to SEK 9.7 (12.0) million for the first nine months of 2005 and to SEK 3.2 (3.4) million for the third quarter.
- Income after financial items was SEK 12.3 (12.2) million, of which SEK 3.0 (3.2) million was for the third quarter.
- Net income for the Group was SEK 12.0 (12.4) million, of which SEK 2.9 million (3.3) was for the third quarter.
- Earnings per share amounted to SEK 0.65 (0.68).
- The equity/assets ratio increased to 83 percent (81).
- Cash flow during the third quarter amounted to SEK 6.2 (-4.5) million, which means that the cash flow for the whole period was also positive, SEK 0.5 (-6.5) million.
- The growth in sales of fertility products in Europe during the third quarter was 21 percent.
- The warrants program directed at the personnel was over-subscribed by 30 percent.
- New sales director for Europe/Asia has been recruited.
Magnus Nilsson CEO
Questions should be addressed to: Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61. Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Cell therapy. The Fertility product area works with nutrient solutions (media) for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Cell therapy product area works with media to enable the use of stem cells for therapeutic purposes.
Vitrolife today has over 80 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there is a subsidiary in Denver, USA. The Vitrolife share is listed on the O-list of the Stockholm Stock Exchange.
Vitrolife AB (publ), Faktorvagen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=145449&fn=wkr0001.pdf